|
1
|
Saif M, Lee Y and Kim R: Harnessing
gemcitabine metabolism: a step towards personalized medicine for
pancreatic cancer. Ther Adv Med Oncol. 4:341–346. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Folkman J: Angiogenesis in cancer,
vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bergers G and Benjamin LE: Tumorigenesis
and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003.
View Article : Google Scholar
|
|
4
|
Maniotis AJ, Folberg R, Hess A, Seftor EA,
Gardner LM, Pe’er J, Trent JM, Meltzer PS, et al: Vascular channel
formation by human melanoma cells in vivo and in vitro:
vasculogenic mimicry. Am J Pathol. 155:739–752. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang W, Lin P, Han C, Cai W, Zhao X and
Sun B: Vasculogenic mimicry contributes to lymph node metastasis of
laryngeal squamous cell carcinoma. J Exp Clin Cancer Res. 60:2–9.
2010.PubMed/NCBI
|
|
6
|
Millimaggi D, Marl M, D’Ascenzo S, Giusti
I, Pavan A and Dolo V: Vasculogenic mimicry of human ovarian cancer
cells: Role of CDl47. Int J Oncol. 35:1423–1428. 2009.PubMed/NCBI
|
|
7
|
Clemente M, Pérez-Alenza MD, Illera JC,
Illera JC and Peña L: Histological, immunohistological, and
ultrastructural description of vasculogenic mimicry in canine
mammary cancer. Vet Pathol. 47:265–274. 2010. View Article : Google Scholar
|
|
8
|
Cai XS, Jia YW, Jiong M and Tang RY: Tumor
blood vessels formation in osteosarcoma: vasculogenesis mimicry.
Chin J Med. 117:94–98. 2004.PubMed/NCBI
|
|
9
|
Yue WY and Chen ZP: Does vasculogenic
mimicry exist in astrocytoma? J Histochem Cytochem. 539:997–1002.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun W, Fan YZ, Zhang WZ and Ge CY: A pilot
histomorphology and hemodynamic of vasculogenic mimicry in
gallbladder carcinomas in vivo and in vitro. J Exp Clin Cancer Res.
46:2–11. 2011.
|
|
11
|
Yue WY and Chen ZP: Vasculogenic mimicry -
potential target for tumor therapy. Ai Zheng. 25:914–916. 2006.(In
Chinese).
|
|
12
|
Shirakawa K, Kobayashi H, Heike Y,
Kawamoto S, Brechbiel MW, Kasumi F, Iwanaga T, et al: Hemodynamics
in vasculogenic mimicry and angiogenesis of inflammatory breast
cancer xenograft. Cancer Res. 62:560–566. 2002.PubMed/NCBI
|
|
13
|
Hendrix MJ, Seftor EA, Meltzer PS, Gardner
LM, Hess AR, Kirschmann DA, Schatteman GC, et al: Expression and
functional signiicance of VE-cadherin in aggressive human melanoma
cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA.
98:8018–8023. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hess AR, Seftor EA, Gruman LM, Kinch MS,
Seftor RE and Hendrix MJ: VE-cadherin regulates EphA2 in aggressive
melanoma cells through a novel signaling pathway: implications for
vasculogenic mimicry. Cancer Biol Ther. 5:228–233. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hess AR, Seftor EA, Gardner LM,
Carles-Kinch K, Schneider GB, Seftor RE, Kinch MS, et al: Molecular
regulation of tumor cell vasculogenic mimicry by tyrosine
phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer
Res. 61:3250–3255. 2001.PubMed/NCBI
|
|
16
|
Margaryan NV, Strizzi L, Abbott DE, Seftor
EA, Rao MS, Hendrix MJ and Hess AR: EphA2 as a promoter of melanoma
tumorigenicity. Cancer Biol Ther. 8:279–288. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hess AR, Margaryan NV, Seftor EA and
Hendrix MJ: Deciphering the signaling events that promote melanoma
tumor cell vasculogenic mimicry and their link to embryonic
vasculogenesis: role of the Eph receptors. Dev Dyn. 236:3283–3296.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Seftor RE, Seftor EA, Koshikawa N, Meltzer
PS, Gardner LM, Bilban M, Stetler-Stevenson WG, et al: Cooperative
interactions of laminin 5 gamma 2 chain, matrix
metalloproteinase-2, and membrane type-1-matrix/metalloproteinase
are required for mimicry of embryonic vasculogenesis by aggressive
melanoma. Cancer Res. 61:6322–6327. 2001.
|
|
19
|
Seftor RE, Seftor EA, Kirschmann DA and
Hendrix MJ: Targeting the tumor microenvironment with chemically
modified tetracyclines: inhibition of laminin 5 gamma 2 chain
promigratory fragments and vasculogenic mimicry. Mol Cancer Ther.
1:1173–1179. 2002.
|
|
20
|
Hess AR, Seftor EA, Seftor RE and Hendrix
MJ: Phosphoinositide 3-kinase regulates membrane type 1-matrix
metalloproteinase (MMP) and MMP-2 activity during melanoma cell
vasculogenic mimicry. Cancer Res. 63:4757–4762. 2003.PubMed/NCBI
|
|
21
|
Sood AK, Fletcher MS, Cofin JE, Yang M,
Seftor EA, Gruman LM, Gershenson DM, et al: Functional role of
matrix metalloproteinases in ovarian tumor cell plasticity. Am J
Obstet Gynecol. 190:899–909. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yue PY, Wong DY and Wu PK: The
angiosuppressive effects of 20(R)-ginsenoside Rg3. Biochem
Pharmacol. 72:437–445. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Han J, Hao F, Hao F, An Y, Xu Y, Xiaokaiti
Y, Pan Y, et al: Ginsenoside Rg3 attenuates cell migration via
inhibition of aquaporin 1 expression in PC-3M prostate cancer
cells. Eur J Pharmacol. 683:27–34. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim JW, Jung SY, Kwon YH, Lee JH, Lee YM,
Lee BY and Kwon SM: Ginsenoside Rg3 attenuates tumor angiogenesis
via inhibiting bioactivities of endothelial progenitor cells.
Cancer Biol Ther. 13:504–515. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang C, Liu L, Yu Y, Chen B, Chen B, Tang
C and Li X: Antitumor effects of ginsenoside Rg3 on human
hepatocellular carcinoma cells. Mol Med Rep. 5:1295–1298.
2012.PubMed/NCBI
|
|
26
|
Lee CK, Park KK, Chung AS and Chung WY:
Ginsenoside Rg3 enhances the chemosensitivity of tumors to
cisplatin by reducing the basal level of nuclear factor erythroid
2-related factor 2-mediated heme oxygenase-1/NAD(P)H quinone
oxidoreductase-1 and prevents normal tissue damage by scavenging
cisplatin-induced intracellular reactive oxygen species. Food Chem
Toxicol. 50:2565–2574. 2012.
|
|
27
|
Liu JP, Lu D, Nicholson RC, Li PY and Wang
F: Toxicity of a novel anti-tumor agent 20(S)-ginsenoside Rg3: a
26-week intramuscular repeated administration study in Beagle dogs.
Food Chem Toxicol. 49:1718–1727. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yuan HD, Quan HY, Zhang Y, Kim SH and
Chung SH: 20(S)-Ginsenoside Rg3-induced apoptosis in HT-29 colon
cancer cells is associated with AMPK signaling pathway. Mol Med
Rep. 3:825–831. 2010.PubMed/NCBI
|
|
29
|
Chen XP, Qian LL, Jiang H and Chen JH:
Ginsenoside Rg3 inhibits CXCR4 expression and related migrations in
a breast cancer cell line. Int J Clin Oncol. 16:519–523. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Greenberg E, Hershkovitz L, Itzhaki O,
Hajdu S, Nemlich Y, Ortenberg R, Gefen N, et al: Regulation of
cancer aggressive features in melanoma cells by microRNAs. PLoS
One. 6:e189362011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Folkman J: Tumor angiogenesis therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Van der Schaft DW, Seftor RE, Seftor EA,
Hess AR, Gruman LM, Kirschmann DA, Yokoyama Y, et al: Effects of
angiogenesis inhibitors on vascular network formation by human
endothelial and melanoma cells. J Natl Cancer Inst. 96:1473–1477.
2004.PubMed/NCBI
|
|
33
|
Chen LX, He YJ, Zhao SZ, Wu JG, Wang JT,
Zhu LM, Lin TT, et al: Inhibition of tumor growth and vasculogenic
mimicry by curcumin through downregulation of the EphA2/PI3K/MMP
pathway in a murine choroidal melanoma model. Cancer Biol Ther.
11:229–235. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang HB, Lin YC, Zeng DE, Lin W, Hong CQ,
Lin WZ and Chen JY: Inhibitory effect of ginsenoside Rg3 on the
tube-like structure formation in human nasopharyngeal carcinoma
HNE-1 cell line in vitro. Zhonghua Zhong Liu Za Zhi. 32:739–742.
2010.(In Chinese).
|
|
35
|
Sun B, Zhang S, Zhang D, Yin X, Wang S, Gu
Y and Wang Y: Doxycycline influences microcirculatin patterns in
B16 melanoma. Exp Biol Med (Maywood). 232:1300–1307. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Guo HC, Bu HQ, Luo J, Wei WT, Liu DL, Chen
H, Tong HF, et al: Emodin potentiates the antitumor effects of
gemcitabine in PANC-1 pancreatic cancer xenograft model in
vivo via inhibition of inhibitors of apoptosis. Int J Oncol.
40:1849–1857. 2012.PubMed/NCBI
|
|
37
|
Ruf W, Seftor EA, Petrovan RJ, Weiss RM,
Gruman LM, Margaryan NV, Seftor RE, et al: Differential role of
tissuefactor pathway inhibitors 1 and 2 in melanoma vasculogenic
mimicry. Cancer Res. 63:5381–5389. 2003.PubMed/NCBI
|
|
38
|
Kirschmann DA, Seftor EA, Hardy KM, Seftor
RE and Hendrix MJ: Molecular pathways: vasculogenic mimicry in
tumor cells: diagnostic and therapeutic implications. Clin Cancer
Res. 18:2726–2732. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hendrix MJ, Seftor EA, Hess AR and Seftor
RE: Vasculogenic mimicry and tumour-cell plasticity: lessons from
melanoma. Nat Rev Cancer. 3:411–421. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Folberg R, Arbieva Z, Moses J, Hayee A,
Sandal T, Kadkol S, Lin AY, et al: Tumor cell plasticity in uveal
melanoma: microenvironment directed dampening of the invasive and
metastatic genotype and phenotype accompanies the generation of
vasculogenic mimicry patterns. Am J Pathol. 169:1376–1389. 2006.
View Article : Google Scholar
|
|
41
|
Fan YZ and Sun W: Molecular regulation of
vasculogenic mimicry in tumors and potential tumor-target therapy.
World J Gastrointest Surg. 2:117–127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu R, Cao Z, Tu J, Pan Y, Shang B, Zhang
G, Bao M, et al: Lycorine hydrochloride inhibits metastatic
melanoma cell-dominant vasculogenic mimicry. Pigment Cell Melanoma
Res. 25:630–638. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shin YM, Jung HJ, Choi WY and Lim CJ:
Antioxidative, anti-inflammatory, and matrix metalloproteinase
inhibitory activities of 20(S)-ginsenoside Rg3 in cultured
mammalian cell lines. Mol Biol Rep. 40:269–279. 2013. View Article : Google Scholar
|
|
44
|
Xu TM, Cui MH, Xin Y, Gu LP, Jiang X, Su
MM, Wang DD, et al: Inhibitory effect of ginsenoside Rg3 on ovarian
cancer metastasis. Chin Med J. 121:1394–1397. 2008.PubMed/NCBI
|
|
45
|
Chen MW, Ni L, Zhao XG and Niu XY: The
inhibition of 20(R)-ginsenoside Rg3 on the expressions of
angiogenesis factors proteins in human lung adenocarcinoma cell
line A549 and HUVEC304 cell. Zhongguo Zhong Yao Za Zhi. 30:357–360.
2005.(In Chinese).
|
